bca-101,pembrolizumab
merck,bicara
['bca101 ', 'solid tumor', 'pembro', 'medsir']
 at #esmo22: bca101, first-in-class bifunctional egfr/tgf fusion protein, is well tolerated and clinically active +/- pembro in pts with advanced solid tumors.
- 1/40 (2,5%) pr, 13/40 (33%) sd in bca101 pts.
- 4/13 (31%) pr, dcr of 9/13 (69%) in bca101 +/- pembro pts. 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM